0001437749-22-008915.txt : 20220413 0001437749-22-008915.hdr.sgml : 20220413 20220413211957 ACCESSION NUMBER: 0001437749-22-008915 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220411 FILED AS OF DATE: 20220413 DATE AS OF CHANGE: 20220413 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rice Michael CENTRAL INDEX KEY: 0001389512 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36362 FILM NUMBER: 22825835 MAIL ADDRESS: STREET 1: C/O BIOLIFE SOLUTIONS, INC. STREET 2: 171 FRONT STREET CITY: OWEGO STATE: NY ZIP: 13827 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC CENTRAL INDEX KEY: 0000834365 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943076866 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4254011400 MAIL ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: BIOLIFE SOLUTION INC DATE OF NAME CHANGE: 20030113 FORMER COMPANY: FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC DATE OF NAME CHANGE: 19920703 4 1 rdgdoc.xml FORM 4 X0306 4 2022-04-11 0000834365 BIOLIFE SOLUTIONS INC BLFS 0001389512 Rice Michael C/O BIOLIFE SOLUTIONS, INC. 3303 MONTE VILLA PARKWAY, SUITE 310 BOTHELL WA 98021 1 1 CEO Common Stock 2022-04-11 4 M 0 10000 1.90 A 337155 D Common Stock 2022-04-11 4 S 0 10000 19.55 D 327155 D Common Stock 2022-04-12 4 M 0 57736 A 384891 D Common Stock 2022-04-13 4 M 0 10000 1.90 A 394891 D Common Stock 2022-04-13 4 S 0 10000 19.06 D 384891 D Employee Stock Option 1.90 2022-04-11 4 M 0 10000 0 D 2026-03-15 Common Stock 10000 70000 D Restricted Stock Award 0 2022-04-12 4 M 0 57736 0 D Common Stock 57736 0 D Employee Stock Option 1.90 2022-04-13 4 M 0 10000 0 D 2026-03-15 Common Stock 10000 60000 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of May 21, 2021. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.13 to $19.98, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The restricted stock was granted pursuant to BioLife Solutions 2013 Performance Incentive Plan (as amended). In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.61 to $19.28, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. On March 15, 2016, the reporting person was granted an option to purchase 100,000 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. /s/ Michael Rice 2022-04-13